Compare Stocks: BHVN, PCVX, IMVT, and APGE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$134.75	$129.31	$35.39 ▼ $134.88	$8.38B	0.35	1.27 million shs	948,283 shs
BHVN Biohaven	$13.91 +3.0%	$14.59	$7.48 ▼ $18.57	$2.09B	1.26	1.94 million shs	2.09 million shs
IMVT Immunovant	$44.37 +0.0%	$39.42	$14.47 ▼ $45.42	$9.16B	0.77	1.10 million shs	846,596 shs
PCVX Vaxcyte	$62.62 +2.1%	$56.43	$29.87 ▼ $65.00	$9.32B	1.23	966,074 shs	1.14 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	+0.15%	+0.36%	+66.03%	+274.10%
BHVN Biohaven	0.00%	-5.14%	-5.04%	+47.27%	-5.15%
IMVT Immunovant	0.00%	+6.10%	+12.70%	+29.93%	+199.39%
PCVX Vaxcyte	0.00%	+7.84%	+12.54%	+32.39%	+100.32%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$134.75	$129.31	$35.39 ▼ $134.88	$8.38B	0.35	1.27 million shs	948,283 shs
BHVN Biohaven	$13.91 +3.0%	$14.59	$7.48 ▼ $18.57	$2.09B	1.26	1.94 million shs	2.09 million shs
IMVT Immunovant	$44.37 +0.0%	$39.42	$14.47 ▼ $45.42	$9.16B	0.77	1.10 million shs	846,596 shs
PCVX Vaxcyte	$62.62 +2.1%	$56.43	$29.87 ▼ $65.00	$9.32B	1.23	966,074 shs	1.14 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	+0.15%	+0.36%	+66.03%	+274.10%
BHVN Biohaven	0.00%	-5.14%	-5.04%	+47.27%	-5.15%
IMVT Immunovant	0.00%	+6.10%	+12.70%	+29.93%	+199.39%
PCVX Vaxcyte	0.00%	+7.84%	+12.54%	+32.39%	+100.32%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	2.20	Hold	$124.43	-7.66% Downside
BHVN Biohaven	2.65	Moderate Buy	$21.75	56.36% Upside
IMVT Immunovant	2.50	Moderate Buy	$44.00	-0.83% Downside
PCVX Vaxcyte	2.50	Moderate Buy	$86.00	37.34% Upside

Current Analyst Ratings Breakdown

Latest BHVN, PCVX, IMVT, and APGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	APGE Apogee Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$81.00 ➝ $135.00
8/12/2026	BHVN Biohaven	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$18.00 ➝ $19.00
8/12/2026	APGE Apogee Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/12/2026	PCVX Vaxcyte	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/11/2026	BHVN Biohaven	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$22.00 ➝ $23.00
8/4/2026	IMVT Immunovant	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$47.00 ➝ $50.00
7/29/2026	IMVT Immunovant	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/17/2026	APGE Apogee Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	PCVX Vaxcyte	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/6/2026	IMVT Immunovant	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/6/2026	PCVX Vaxcyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$13.23 per share	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	$0.39 per share	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.19 per share	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$20.51 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$255.84M	-$4.34	N/A	N/A	N/A	N/A	-29.88%	-28.08%	11/9/2026 (Estimated)
BHVN Biohaven	-$738.82M	-$4.64	N/A	N/A	N/A	N/A	-1,328.94%	-138.27%	11/9/2026 (Estimated)
IMVT Immunovant	-$505.61M	-$2.82	N/A	N/A	N/A	N/A	-69.59%	-62.49%	11/9/2026 (Estimated)
PCVX Vaxcyte	-$766.63M	-$7.63	N/A	N/A	N/A	N/A	-37.56%	-33.62%	11/3/2026 (Estimated)

Latest BHVN, PCVX, IMVT, and APGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	APGE Apogee Therapeutics	-$1.07	-$1.14	-$0.07	-$1.14	$10.00 million	N/A
8/10/2026	Q2 2026	BHVN Biohaven	-$0.7610	-$0.91	-$0.1490	-$0.91	$0.49 million	N/A
8/6/2026	Q1 2027	IMVT Immunovant	-$0.6289	-$0.75	-$0.1211	-$0.75	$7.10 million	$7.10 million
8/5/2026	Q2 2026	PCVX Vaxcyte	-$2.06	-$1.97	+$0.09	-$1.97	$12.50 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	26.44	26.44
BHVN Biohaven	21.23	4.73	4.73
IMVT Immunovant	N/A	7.27	7.27
PCVX Vaxcyte	N/A	5.72	5.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
BHVN Biohaven	88.78%
IMVT Immunovant	47.08%
PCVX Vaxcyte	96.78%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	24.30%
BHVN Biohaven	13.80%
IMVT Immunovant	1.90%
PCVX Vaxcyte	3.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	62.20 million	47.09 million	Optionable
BHVN Biohaven	239	151.04 million	130.20 million	Optionable
IMVT Immunovant	120	206.55 million	202.63 million	Optionable
PCVX Vaxcyte	160	148.80 million	143.89 million	Optionable

BHVN, PCVX, IMVT, and APGE Headlines

Recent News About These Companies

Deutsche Bank AG Makes New $15.02 Million Investment in Vaxcyte, Inc. $PCVX

August 23 at 3:36 AM | marketbeat.com

BlackRock Inc. Invests $701.52 Million in Vaxcyte, Inc. $PCVX

August 23 at 3:28 AM | marketbeat.com

Vaxcyte: Not Enough Safety Margin With Current Price

August 18, 2026 | seekingalpha.com

If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long Gone

August 16, 2026 | 247wallst.com

Vaxcyte (NASDAQ:PCVX) Stock Rating Upgraded by Zacks Research

August 14, 2026 | marketbeat.com

Assenagon Asset Management S.A. Decreases Stock Holdings in Vaxcyte, Inc. $PCVX

August 12, 2026 | marketbeat.com

Bank of America Corp DE Increases Position in Vaxcyte, Inc. $PCVX

August 10, 2026 | marketbeat.com

Vaxcyte (NASDAQ:PCVX) Stock Rating Upgraded by Wall Street Zen

August 8, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Vaxcyte (PCVX), Black Diamond Therapeutics (BDTX) and Sarepta Therapeutics (SRPT)

August 7, 2026 | theglobeandmail.com

Vaxcyte (PCVX) Receives a Buy from Guggenheim

August 7, 2026 | theglobeandmail.com

The Manufacturers Life Insurance Company Trims Stock Position in Vaxcyte, Inc. $PCVX

August 7, 2026 | marketbeat.com

Vaxcyte, Inc. $PCVX Shares Acquired by Dimensional Fund Advisors LP

August 7, 2026 | marketbeat.com

Insider Selling: Vaxcyte (NASDAQ:PCVX) COO Sells 2,250 Shares

August 6, 2026 | insidertrades.com